NASDAQ:ACRS Aclaris Therapeutics (ACRS) Stock Price, News & Analysis $1.31 +0.06 (+4.80%) Closing price 04:00 PM EasternExtended Trading$1.31 0.00 (0.00%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aclaris Therapeutics Stock (NASDAQ:ACRS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aclaris Therapeutics alerts:Sign Up Key Stats Today's Range$1.25▼$1.3350-Day Range$1.08▼$1.9652-Week Range$0.95▼$5.17Volume1.06 million shsAverage Volume1.18 million shsMarket Capitalization$141.85 millionP/E RatioN/ADividend YieldN/APrice Target$11.67Consensus RatingBuy Company OverviewAclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Read More… Aclaris Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreACRS MarketRank™: Aclaris Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 360th out of 912 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingAclaris Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAclaris Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Aclaris Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aclaris Therapeutics are expected to grow in the coming year, from ($0.82) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aclaris Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aclaris Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAclaris Therapeutics has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.09% of the float of Aclaris Therapeutics has been sold short.Short Interest Ratio / Days to CoverAclaris Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Aclaris Therapeutics has recently decreased by 34.78%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAclaris Therapeutics does not currently pay a dividend.Dividend GrowthAclaris Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.09% of the float of Aclaris Therapeutics has been sold short.Short Interest Ratio / Days to CoverAclaris Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Aclaris Therapeutics has recently decreased by 34.78%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News Sentiment1.40 News SentimentAclaris Therapeutics has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Aclaris Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for ACRS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Aclaris Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aclaris Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of Aclaris Therapeutics is held by insiders.Percentage Held by Institutions98.34% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aclaris Therapeutics' insider trading history. Receive ACRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRS Stock News HeadlinesAclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8 at 6:50 AM | globenewswire.comAclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical OfficerMay 1, 2025 | msn.comThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.May 8, 2025 | Colonial Metals (Ad)Aclaris Therapeutics appoints new Chief Medical OfficerApril 30, 2025 | uk.investing.comAclaris Therapeutics, Inc.: Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical OfficerApril 29, 2025 | finanznachrichten.deAclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical OfficerApril 29, 2025 | globenewswire.comStrong week for Aclaris Therapeutics (NASDAQ:ACRS) shareholders doesn't alleviate pain of three-year lossApril 25, 2025 | uk.finance.yahoo.comAclaris Therapeutics’ IND for ATI-052 candidate granted FDA clearanceApril 23, 2025 | markets.businessinsider.comSee More Headlines ACRS Stock Analysis - Frequently Asked Questions How have ACRS shares performed this year? Aclaris Therapeutics' stock was trading at $2.48 on January 1st, 2025. Since then, ACRS shares have decreased by 47.2% and is now trading at $1.31. View the best growth stocks for 2025 here. How were Aclaris Therapeutics' earnings last quarter? Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced its quarterly earnings data on Tuesday, May, 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.07. Aclaris Therapeutics had a negative net margin of 136.65% and a negative trailing twelve-month return on equity of 40.26%. Who are Aclaris Therapeutics' major shareholders? Top institutional investors of Aclaris Therapeutics include Decheng Capital LLC (3.73%), Assenagon Asset Management S.A. (0.63%), Alps Advisors Inc. (0.07%) and Cannon Global Investment Management LLC (0.03%). Insiders that own company stock include Braden Michael Leonard, Neal Walker, Anand Mehra, Andrew N Schiff, Joseph Monahan, James Loerop, Douglas J Manion and Kevin Balthaser. View institutional ownership trends. How do I buy shares of Aclaris Therapeutics? Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aclaris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aclaris Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Netflix (NFLX) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/06/2025Today5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACRS CIK1557746 Webwww.aclaristx.com Phone(484) 324-7933Fax484-320-2344Employees100Year Founded2012Price Target and Rating Average Stock Price Target$11.67 High Stock Price Target$20.00 Low Stock Price Target$7.00 Potential Upside/Downside+800.9%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,480,000.00 Net Margins-136.65% Pretax Margin-138.00% Return on Equity-40.26% Return on Assets-31.71% Debt Debt-to-Equity RatioN/A Current Ratio7.03 Quick Ratio7.03 Sales & Book Value Annual Sales$18.72 million Price / Sales7.49 Cash FlowN/A Price / Cash FlowN/A Book Value$2.22 per share Price / Book0.58Miscellaneous Outstanding Shares108,281,000Free Float66,859,000Market Cap$140.22 million OptionableOptionable Beta0.42 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:ACRS) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersTrump's $500B plan is fueling these monthly dividendsSomething extraordinary happened just 24 hours after Trump returned to office... He signed a document that ...Investors Alley | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredBitcoin Just Broke $100K – Are You Positioned?This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWarning: Massive IPO Predicted for May 14?The #1 venture capitalist in America predicts that the biggest IPO in history will take place on Wednesday, Ma...Paradigm Press | SponsoredOne Stock Gold Blueprint to Survive the Market ChaosOne Stock Gold Blueprint to Survive the Market Chaos Markets are volatile, uncertainty is everywhere, and A...InvestorPlace | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.